Establishment Labs Q3 revenue up 34%, beats estimates
Overview
Breast aesthetics device maker's Q3 revenue rose 34% yr/yr, beating analyst expectations
Company posted Q3 net loss and loss per share
Company achieved first positive operating and free cash flow in Q3
Outlook
Company raises 2026 revenue guidance to over $274 mln from $269-271 mln
Company expects 2026 adjusted gross margin of about 70.7%
Company maintains 2026 adjusted operating expenses forecast at $195 mln to $200 mln
Result Drivers
U.S. AND MINIMALLY INVASIVE GROWTH - Co said Q3 revenue growth was driven by 119% increase in U.S. sales and 124% rise in minimally invasive platform revenue
SALES MIX IMPACT - Higher-margin U.S. and minimally invasive sales supported gross margin, but stronger OUS distributor sales contributed at lower margins
OPERATING LEVERAGE - Co said adjusted operating expenses fell as a percentage of revenue, reflecting improved operating leverage
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $71.99 mln | $66.46 mln (10 Analysts) |
Q3 Loss Per Share | Miss | $0.35 | $0.26 (10 Analysts) |
Q3 Net Loss | Miss | $10.71 mln | $7.95 mln (10 Analysts) |
Q3 Income From Operations | Miss | -$2.62 mln | -$1.18 mln (9 Analysts) |
Q3 Gross Profit | $49.71 mln | ||
Q3 Pretax Loss | $10.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Establishment Labs Holdings Inc. is $103.00, about 49.3% above its October 28 closing price of $68.97
Reuters Recommended Reads
Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)